biotech

152498601

Tesaro Rises on Positive FDA Results

Tesaro Inc. (NASDAQ: TSRO) shares reacted positively in the market Wednesday as positive study results have been released surrounding its lead product. The company announced that the U.S. Food and ...
Read Full Story »
software

What Illumina Gets With GenoLogics Life Science Software

Tuesday morning, Illumina Inc. (NASDAQ: ILMN) announced the completion of its acquisition of GenoLogics Life Science Software. Illumina President Francis deSouza said: We look forward to working with the talented ...
Read Full Story »
health care

Is the BioLife Move Sustainable?

BioLife Solutions Inc. (NASDAQ: BLFS) was up solidly in Monday’s trading session on positive results from a Phase 3 study. The company announced that its customer TiGenix NV recently disclosed ...
Read Full Story »
thumbs up

Why Recent IPO Aimmune Therapeutics Could Rise 50% to 100%

Aimmune Therapeutics Inc. (NASDAQ: AIMT) announced the closing of its initial public offering of nearly 11.5 million shares at the price of $16 per share. With the closing of the ...
Read Full Story »
biotech

Is the Move in Vital Therapies Sustainable?

Vital Therapies Inc. (NASDAQ: VTL) made a big run in the market on Monday morning following additional data from the 16th International Symposium on Albumin Dialysis in Liver Disease. The ...
Read Full Story »
initial public offering

Cytomx Files for IPO

Cytomx Therapeutics Inc. filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given in the filing, but the ...
Read Full Story »
health care

The Medicines Company and Alnylam Rise on Positive Phase 1 Results

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) and The Medicines Company (NASDAQ: MDCO) made waves Monday morning despite downward pressure from the broad markets. These companies announced positive initial results from their ...
Read Full Story »
fda_logo

5 Big FDA Decisions Expected in September

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, similar to that ...
Read Full Story »
generic drugs

How Amgen Can Disrupt the Market for Cholesterol Drugs

Amgen Inc. (NASDAQ: AMGN), known as a leading biotech in its field, made waves in the market on Friday morning. This biotech giant has the potential to disrupt the market ...
Read Full Story »
health care

Acelity Files for Initial Public Offering

Acelity Holdings Inc. has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given in the filing, but ...
Read Full Story »
Biotechnology word cloud

Short Sellers Become More Focused in Major Biotechs

The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Organovo 3D bioprinter

Mirna Therapeutics Files for IPO

Mirna Therapeutics Inc. has filed its paperwork with the Securities and Exchange Commission (SEC) to conduct an initial public offering (IPO) for its shares. The company has applied to list ...
Read Full Story »
research

Epizyme Beats Out the Market With FDA Approval

Epizyme Inc. (NASDAQ: EPZM) survived the market carnage of what was Monday morning’s trading session. In fact this biopharma came out of the fray better off than when it went ...
Read Full Story »
Sad lonely pensive old senior woman

Applied Genetic Solidifies Deal With Biogen

Applied Genetic Technologies Corp. (NASDAQ: AGTC) announced that the Biogen Inc. (NASDAQ: BIIB) equity investment as part of their collaboration has closed. As per the agreement that was set in ...
Read Full Story »
research

Omeros Shares Doubling on Positive Phase 2 Data

Omeros Corp. (NASDAQ: OMER) is flying high in Tuesday’s trading session with shares practically doubling on positive phase 2 news. The company announced additional positive data in the it’s phase ...
Read Full Story »